Next Science (ASX:NXS) Debt-to-Equity : 0.08 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science Debt-to-Equity?

Next Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.41 Mil. Next Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$1.03 Mil. Next Science's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$19.16 Mil. Next Science's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Next Science's Debt-to-Equity or its related term are showing as below:

ASX:NXS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.15
Current: 0.08

During the past 6 years, the highest Debt-to-Equity Ratio of Next Science was 0.15. The lowest was 0.02. And the median was 0.03.

ASX:NXS's Debt-to-Equity is ranked better than
75.06% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs ASX:NXS: 0.08

Next Science Debt-to-Equity Historical Data

The historical data trend for Next Science's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Debt-to-Equity Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

0.03

0.15

0.08

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					0.03	0.09	0.15	-448.24	0.08

Competitive Comparison of Next Science's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Next Science's Debt-to-Equity falls into.

Next Science Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Next Science's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.411	+	1.026)	/	19.155
	=	0.08

Next Science's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.411	+	1.026)	/	19.155
	=	0.08

Next Science (ASX:NXS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Next Science Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Next Science's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines